Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements include,
but are not limited to, references to the planned scope and trial design of
the ANA773 clinical trial, the belief that ANA773 holds promise for the
treatment of a range of malignancies, and that it may have utility when
combined with targeted agents, therapeutic antibodies and/or chemotherapy,
Anadys' ability to identify a dose and schedule for Phase II investigation
by the end of this year and the ability to develop ANA773 as a therapy for
patients with cancer. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause Anadys'
actual results to be materially different from historical results or from
any results expressed or implied by such forward-looking statements. For
example, the results of preclinical studies may not be predictive of future
results, and Anadys cannot provide any assurances that ANA773 will not have
unforeseen safety issues, will have favorable results in future clinical
trials or will receive regulatory approval. In addition, Anadys' results
may be affected by risks related to competition from other biotechnology
and pharmaceutical companies, its effectiveness at managing its financial
resources, its ability to successfully develop and market products,
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved